Generation Bio Co. (GBIO)
Largest Insider Buys in Sector
GBIO Stock Price History Chart
GBIO Stock Performance
About Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Generation Bio Co.
Over the last 12 months, insiders at Generation Bio Co. have bought $0 and sold $26,332 worth of Generation Bio Co. stock.
On average, over the past 5 years, insiders at Generation Bio Co. have bought $34.75M and sold $14.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $14,339 was made by Appelhans Dannielle (director) on 2023‑12‑08.
List of Insider Buy and Sell Transactions, Generation Bio Co.
| 2024-07-01 | Sale | CHIEF OPERATING OFFICER | 6,719 0.0099% | $2.74 | $18,410 | 0.00% | ||
| 2024-01-02 | Sale | CHIEF STRATEGY OFFICER | 2,445 0.0032% | $1.62 | $3,961 | +38.27% | ||
| 2024-01-02 | Sale | CHIEF OPERATING OFFICER | 2,445 0.0032% | $1.62 | $3,961 | +38.27% | ||
| 2023-12-08 | director | 8,000 0.0127% | $1.79 | $14,339 | +47.80% | |||
| 2023-12-04 | director | 150,000 0.2255% | $1.50 | $225,000 | +68.00% | |||
| 2023-12-04 | director | 12,000 0.018% | $1.50 | $18,000 | +68.00% | |||
| 2023-12-01 | director | 192,960 0.2723% | $1.31 | $252,778 | +76.22% | |||
| 2023-12-01 | director | 100,000 0.1551% | $1.44 | $144,000 | +76.22% | |||
| 2023-12-01 | director | 88,495 0.1344% | $1.41 | $124,778 | +76.22% | |||
| 2023-08-23 | Sale | CHIEF OPERATING OFFICER | 3,116 0.0046% | $4.93 | $15,362 | -43.73% | ||
| 2023-07-03 | Sale | CHIEF STRATEGY OFFICER | 3,116 0.0054% | $5.29 | $16,484 | -40.51% | ||
| 2023-04-25 | Sale | CHIEF OPERATING OFFICER | 2,914 0.0049% | $4.61 | $13,434 | -27.77% | ||
| 2023-01-26 | Sale | CHIEF OPERATING OFFICER | 2,695 0.0044% | $5.56 | $14,984 | -26.23% | ||
| 2023-01-10 | Sale | CHIEF OPERATING OFFICER | 1,865 0.003% | $4.57 | $8,523 | -9.01% | ||
| 2023-01-09 | Sale | CHIEF STRATEGY OFFICER | 1,865 0.0035% | $5.11 | $9,530 | -6.05% | ||
| 2022-10-27 | Sale | CHIEF OPERATING OFFICER | 2,914 0.0051% | $5.03 | $14,657 | -5.45% | ||
| 2022-09-29 | Sale | CHIEF OPERATING OFFICER | 2,828 0.0049% | $5.24 | $14,819 | -5.50% | ||
| 2022-03-09 | 8,126 0.0137% | $4.71 | $38,273 | +14.72% | ||||
| 2021-09-29 | Sale | director | 16,586 0.0297% | $24.59 | $407,850 | -72.60% | ||
| 2021-09-29 | Sale | 10 percent owner | 16,586 0.0297% | $24.59 | $407,850 | -72.60% |
Insider Historical Profitability
| Invus Public Equities, L.P. | 10 percent owner | 2814191 4.2133% | $1.19 | 1 | 0 | +47.36% |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10 percent owner | 2112546 3.1628% | $1.19 | 1 | 0 | +47.36% |
| Seybold William | 10 percent owner | 1918819 2.8728% | $1.19 | 1 | 0 | +47.36% |
| Zone Healthcare Holdings, LLC | 10 percent owner | 1918819 2.8728% | $1.19 | 1 | 0 | +47.36% |
| Casdin Capital, LLC | 10 percent owner | 1611215 2.4123% | $1.19 | 1 | 0 | +47.36% |
Institutional Investor Ownership
| T. Rowe Price | $36.14M | 13.35 | 8.88M | +28.19% | +$7.95M | <0.01 | |
| Atlas Venture Life Science Advisors Llc | $33.7M | 12.45 | 8.28M | 0% | +$0 | 3.13 | |
| Fidelity Investments | $21.71M | 8.02 | 5.33M | -0.34% | -$73,829.80 | <0.01 | |
| Bellevue Group | $15.72M | 5.8 | 3.86M | +6.76% | +$995,094.63 | 0.24 | |
| BlackRock | $12.41M | 4.58 | 3.05M | -3.77% | -$486,633.64 | <0.0001 |